ArticleAnnals of medicine2026
Performance of the Phoenix Sepsis Score for in-hospital mortality in critically ill pediatric oncology patients with suspected infection.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric oncology patients with infection face a high risk of death. Although the Phoenix Sepsis Score (PSS) has recently been introduced as an organ dysfunction score for pediatric sepsis, its performance in pediatric oncology populations remains insufficiently characterized.
methodsThis retrospective study enrolled pediatric oncology patients admitted to the pediatric intensive care unit (PICU) with suspected infection. The performance of the PSS was evaluated and compared with other pediatric critical care scores for discrimination of in-hospital mortality.
resultsThe study cohort comprised 224 patients, accounting for 254 PICU admissions. The overall hospital mortality rate was 17.7%. All scoring systems except the Pediatric Risk of Mortality III (PRISM III) score demonstrated good discrimination. Phoenix-8 showed the highest area under the curve (AUC) (0.855, 95% CI: 0.791-0.919), followed by PSS (0.837) and Pediatric Sequential Organ Failure Assessment (pSOFA) score (0.836). Phoenix-8 had significantly higher AUCs than PHO-Phoenix and PRISM III; differences among the other scoring systems were not statistically significant. Sensitivity analyses were broadly consistent with the primary analysis but showed lower AUCs after inclusion of deaths following discontinuation of life-sustaining therapy.
conclusionsThe PSS showed good discrimination for in-hospital mortality in PICU-admitted pediatric oncology patients with infection, with an AUC of similar magnitude to those of pSOFA and PELOD-2. Its lower data requirements may support its use as a clinically feasible tool for mortality risk assessment in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.